Core operating profit grew 10% year-over-year, outpacing 6% sales growth, with margin expansion and strong contributions from both Pharma and Diagnostics. Pipeline momentum remains high, with five FDA priority reviews and major launches in both divisions. Full-year guidance for mid-single-digit sales and high single-digit EPS growth is reaffirmed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.